JOM KITA KE POLITEKNIK

Renal Function and Coronary Bypass Surgery in Patients With Ischemic Heart Failure (Record no. 1715)

MARC details
042 ## - AUTHENTICATION CODE
Authentication code dc
100 10 - MAIN ENTRY--PERSONAL NAME
Personal name Doenst, Torsten
Relator term author
9 (RLIN) 965
245 00 - TITLE STATEMENT
Title Renal Function and Coronary Bypass Surgery in Patients With Ischemic Heart Failure
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Date of publication, distribution, etc. 2022-02.
500 ## - GENERAL NOTE
General note /pmc/articles/PMC7541611/
500 ## - GENERAL NOTE
General note /pubmed/32386761
520 ## - SUMMARY, ETC.
Summary, etc. OBJECTIVE: Chronic kidney disease (CKD) is a known risk factor in cardiovascular (CV) disease but its influence on treatment effect of bypass surgery (CABG) remains unclear. We assessed the influence of CKD on 10-year mortality and CV-outcomes in ischemic HF patients treated with medical therapy (MED) with or without CABG. METHODS: We calculated baseline estimated glomerular filtration rate (eGFR, CKD-EPI formula, CKD stages 1-5) from 1,209 patients randomized to MED or CABG in the Surgical Treatment for IsChemic Heart failure (STICH) trial and assessed its effect on outcome. RESULTS: In the overall STICH cohort, patients in CKD stages 3-5 were older than those in stages 1/2 (66-71 vs. 54-59 years) and had more comorbidities. Multivariable modeling revealed an inverse association between eGFR and risk of death, CV death and/or CV-rehospitalization (all p<0.001, but not for stroke, p=0.697). Baseline characteristics of the two treatment arms were equal for each CKD stage. There were significant improvements in death or CV-rehospitalization with CABG (Stage 1: HR 0.71, CI 0.53-0.96, p=0.02; Stage 2: HR 0.71, CI 0.59-0.84, p<0.0001; Stage 3: HR 0.76, CI 0.53-0.96, p=0.03). These data were inconclusive in stages 4/5 for insufficient patient numbers (N=28). There was no significant interaction of eGFR with the treatment effect of CABG (p=0.25 for death and 0.54 for death or CV-rehospitalization). CONCLUSIONS: Chronic kidney disease is an independent risk factor for mortality in patients with ischemic HF with or without CABG. However, mild to moderate CKD does not appear to influence long-term treatment effects of CABG.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction
546 ## - LANGUAGE NOTE
Language note en
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element Article
655 7# - INDEX TERM--GENRE/FORM
Genre/form data or focus term Text
Source of term local
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Haddad, Haissam
Relator term author
9 (RLIN) 966
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Stebbins, Amanda
Relator term author
9 (RLIN) 967
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Hill, James A.
Relator term author
9 (RLIN) 968
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Velazquez, Eric J.
Relator term author
9 (RLIN) 969
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Lee, Kerry L.
Relator term author
9 (RLIN) 970
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Rouleau, Jean L.
Relator term author
9 (RLIN) 971
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Sopko, George
Relator term author
9 (RLIN) 972
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Farsky, Pedro S.
Relator term author
9 (RLIN) 973
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Al-Khalidi, Hussein R.
Relator term author
9 (RLIN) 974
786 0# - DATA SOURCE ENTRY
Note J Thorac Cardiovasc Surg
856 41 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1016/j.jtcvs.2020.02.136">http://dx.doi.org/10.1016/j.jtcvs.2020.02.136</a>
Public note Connect to this object online.

No items available.